Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06330064 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
A Phase 2 study of Recurrent or Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT06330064: Recruiting Phase 2 study of Recurrent or Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
NCT06330064 is a Phase 2 study of Recurrent or Metastatic Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 520 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (291% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06330064, a Phase 2 study of Recurrent or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.
Primary Outcome
ORR is defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG Ifinatamab deruxtecan
Study Locations (20)
California
- Los Angeles Cancer Network - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Pih Health Hematology Medical Oncology - Whittier
New York
- NYU Langone Health - New York
- Icahn School of Medicine At Mount Sinai Prime - New York
- Clinical Research Alliance - Westbury
Tennessee
- Tn Gynecologic Oncology Group, Llc - Chattanooga
- The West Clinic - Germantown
- SCRI Oncology Partners - Nashville
Texas
- Texas Oncology - West Texas - Amarillo
- Texas Oncology, P.A. - Dallas
- Texas Oncology Gulf Coast - Pearland
Other
- DIABAID - Buenos Aires
- Hospital Aleman - Buenos Aires
- Hospital Sirio Libanes - Caba
Illinois
- Orchard Healthcare Research Inc. - Skokie
Minnesota
- M Health Fairview University of Minnesota Medical Center - Minneapolis
Utah
- University of Utah Hospitals & Clinics - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2028-07-25 |
| Phase | Phase 2 |
What NCT06330064 shows while recruiting
NCT06330064 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (291% higher).
The record links to 1 condition, with Recurrent or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Ifinatamab deruxtecan is the first listed.
NCT06330064 names 20 study sites across 10 states, led by California, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06330064 about?
NCT06330064 is a clinical study titled "A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)". This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarci...
What is the current status of trial NCT06330064?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 520 participants. The study started on 2024-04-10. Estimated completion is 2028-07-25.
What conditions does trial NCT06330064 study?
This clinical trial studies the following conditions: Recurrent or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06330064?
The interventions under investigation include: Ifinatamab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06330064?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06330064 being conducted?
This trial has 20 study locations across California, Illinois, Minnesota, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06330064's enrollment target sits among peer trials
520 65th of 2000 higher than 1,935 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI